专利检索 ipc:"C07K14/82" 第 5 页

41.

发明授权
Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers 有权

公开(公告)号：US10239925B2

公开(公告)日：2019-03-26

申请号：US16101081

申请日：2018-08-10

申请人： IMMATICS BIOTECHNOLOGIES GMBH

发明人： Andrea Mahr , Toni Weinschenk , Helen Hoerzer , Oliver Schoor , Jens Fritsche , Harpreet Singh

IPC分类号： A61K39/395 , C07K14/47 , C07K14/82 , C07K14/705 , A61K35/17 , G01N33/569 , C12P21/02 , C07K16/30 , C12Q1/6881 , C07K16/32 , G01N33/574 , C12Q1/6886 , C07K16/28 , C07K16/18 , C07K14/74 , A61K39/00 , C12N15/115 , C07K7/08 , C07K7/06 , C12N5/0783 , A61K35/12 , A61K38/00

摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

42.

发明授权
Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers 有权

公开(公告)号：US10227388B2

公开(公告)日：2019-03-12

申请号：US15199182

申请日：2016-06-30

申请人： immatics biotechnologies GmbH

发明人： Andrea Mahr , Toni Weinschenk , Helen Hoerzer , Oliver Schoor , Jens Fritsche , Harpreet Singh

IPC分类号： C07K14/47 , C07K14/74 , A61K39/00 , C12N15/115 , C07K7/08 , C07K7/06 , C07K16/28 , C12N5/0783 , A61K35/17 , C07K16/30 , C12P21/02 , C12Q1/6881 , G01N33/569 , C07K14/82 , C07K16/32 , C12Q1/6886 , G01N33/574 , C07K14/705 , C07K16/18 , A61K38/00 , A61K35/12

摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

43.

发明授权
Interference peptides and use thereof 有权

公开(公告)号：US10201610B2

公开(公告)日：2019-02-12

申请号：US14518632

申请日：2014-10-20

申请人： The University of Western Australia

发明人： Pilar Blancafort

IPC分类号： C07K4/00 , A61K38/00 , A61K45/06 , C07K14/82 , C07K14/47

摘要： A purified and isolated peptide comprises an amino acid sequence of SEQ ID NOs: 1 to 8. A method is also provided for preventing interaction, e.g. binding, of EN1 with EPRS in a cell by introducing, into the cell, a peptide having a sequence of SEQ ID NOs: 1 to 8, which results in the peptide interacting with EPRS thereby preventing an interaction of EPRS with EN1. Apoptosis can be induced in a cell expressing either or both of EN1 and EN2, by introducing into the cell, a peptide of SEQ ID NOs: 1 to 8.

44.

发明申请
HLA-A24 AGONIST EPITOPES OF MUC1-C ONCOPROTEIN AND COMPOSITIONS AND METHODS OF USE 审中-公开

公开(公告)号：US20190002513A1

公开(公告)日：2019-01-03

申请号：US16034654

申请日：2018-07-13

申请人： The USA, as represented by the Secretary, Dept. of Health and Human Services

发明人： Jeffrey Schlom , Kwong-Yok Tsang

IPC分类号： C07K14/47 , C12N7/00 , A61K38/19 , A61K38/20 , A61K38/22 , A61K31/00 , C07K14/82 , A61K45/06 , A61K39/39 , A61K39/00 , A61K38/21 , A61K38/00

CPC分类号： C07K14/4727 , A61K31/00 , A61K38/00 , A61K38/191 , A61K38/193 , A61K38/195 , A61K38/20 , A61K38/217 , A61K38/22 , A61K39/0011 , A61K39/39 , A61K45/06 , A61K2039/5154 , A61K2039/53 , A61K2039/55588 , C07K14/82 , C07K2319/00 , C12N7/00 , C12N2710/24143 , C12N2710/24171 , A61K2300/00

摘要： The invention provides a human cytotoxic T lymphocyte (CTL) agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), and/or in vaccine or other composition for the prevention or therapy of cancer. The invention further provides a nucleic acid encoding the peptide, protein, or polypeptide, a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide, nucleic acid, or vector, and compositions thereof.

45.

发明申请
CYCLIC PEPTIDE BINDER AGAINST ONCOGENIC K-RAS 审中-公开

公开(公告)号：US20180319844A1

公开(公告)日：2018-11-08

申请号：US16031840

申请日：2018-07-10

申请人： California Institute of Technology

发明人： Ryan K. Henning , Ashwin N. Ram , Samir Das , Arundhati Nag , James R. Heath

IPC分类号： C07K7/64 , C07K7/06 , C07K14/82 , G01N33/574

CPC分类号： C07K7/64 , A61K38/00 , C07K7/06 , C07K14/82 , G01N33/5748 , G01N2333/82 , G01N2333/914 , G01N2500/04

摘要： Cyclic peptides represented by (Formula 1) selectively bind the oncoprotein K-Ras G12D in vitro and in cellulo, where Z1 and Z2 are each L-propargylglycine (Pm), azidoornithine (OrnN3), or L-azidolysine (Az4), and V1-V2-V3-V4-V5 is an amino acid variable region having a sequence selected from the group consisting of SEQ ID NOs: 1-20.

46.

发明申请
POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF AS A DRUG TARGET FOR PRODUCING DRUGS AND BIOLOGICS 审中-公开

公开(公告)号：US20180298109A1

公开(公告)日：2018-10-18

申请号：US15882240

申请日：2018-01-29

申请人： Compugen Ltd.

发明人： Anat COHEN-DAYAG , Merav BEIMAN , Liat DASSA , Marina BUBIS , Shirley SAMEACH GREENWALD , Dalit LANDESMAN-MILO , Cynthia KOIFMAN , Ofer LEVY , Sergey NEMZER , Tania PERGAM , Yaron KINAR , Zurit LEVINE , Avi ROSENBERG , Galit ROTMAN , Eve MONTIA , Amit NOVIK , Amir TOPORIK , Shira WALACH

IPC分类号： C07K16/30 , G01N33/574 , A61K39/00 , A61K39/39 , A61K39/395 , A61K45/06 , A61N5/10 , A61K31/7088 , G01N33/564 , C07K16/28 , C07K14/82 , C07K14/705 , C07K14/47 , C07K14/00 , A61K38/00

摘要： This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants which are suitable targets for immunotherapy, cancer therapy, and drug development.

47.

发明授权
Cyclic peptide binder against oncogenic K-Ras 有权

公开(公告)号：US10017540B2

公开(公告)日：2018-07-10

申请号：US15068528

申请日：2016-03-11

申请人： CALIFORNIA INSTITUTE OF TECHNOLOGY

发明人： Ryan K. Henning , Ashwin N. Ram , Samir Das , Arundhati Nag , James R. Heath

IPC分类号： A61K38/12 , A61P35/00 , C07K7/64 , G01N33/574 , C07K14/82 , C07K7/06 , A61K38/00

CPC分类号： C07K7/64 , A61K38/00 , C07K7/06 , C07K14/82 , G01N33/5748 , G01N2333/82 , G01N2333/914 , G01N2500/04

摘要： Cyclic peptides represented by (Formula 1) selectively bind the oncoprotein K-Ras G12D in vitro and in cellulo, where Z1 and Z2 are each L-propargylglycine (Pra), azidoornithine (OrnN3), or L-azidolysine (Az4), and V1-V2-V3-V4-V5 is an amino acid variable region having a sequence selected from the group consisting of SEQ ID NOs: 1-20.